SEARCH

Health » Medicine

Updated: March 8, 2010 18:45 IST

Roche suspends arthritis drug study after deaths

AP
print   ·   T  T  
Franz B. Humer, chairman of the board of Roche, speaks during the general assembly of Swiss pharmaceutical company Roche Holding AG, in Basel, Switzerland, last week. Photo: AP.
Franz B. Humer, chairman of the board of Roche, speaks during the general assembly of Swiss pharmaceutical company Roche Holding AG, in Basel, Switzerland, last week. Photo: AP.

Swiss pharmaceutical company Roche Group said on Monday it has suspended a late—stage trial for a new rheumatoid arthritis and lupus drug after several patients died from infections.

Roche said the drug, ocrelizumab, was developed together with Biogen Idec with headquarters in Cambridge, Massachusetts.

A review found “the safety risk outweighs the benefits observed in these specific patient populations at this time” after detecting “serious and opportunistic infections, some of which were fatal,” Basel—based Roche said.

It declined immediately to say how many patients died, where and when.

The company said it was still testing ocrelizumab for patients with relapsing remitting multiple sclerosis

Roche shares were down 0.6 percent at 179.60 Swiss francs ($167.54) on the Zurich exchange.



O
P
E
N

close

Recent Article in Medicine

In this undated photo released on October 18, 2014 photo, scientists at the National Microbiology Lab in Winnipeg, Manitoba, prepare an experimental Ebola vaccine for shipment to the World Health Organisation in Geneva. WHO says five more experimental vaccines will start being tested in March 2015.

5 more Ebola vaccines to be tested in March: WHO

The agency, however, warns that it’s not clear whether any of these will work against the deadly virus that has already killed over 4,800 people this year. »